

Supplemental Table 4. Associations between aging constructs and cancer prevalence in 2016; cancer cases diagnosed within two years of blood collection were excluded, HRS

Sample A^a				
Aging constructs	No. of cancer survivors ^b	No. of controls ^b	OR (95% CI) per 1 SD increase in aging constructs	
			Model 1 ^c	Model 2 ^d
KDM-BA-Accel (SD = 3.81 years)	845	4,461	1.05 (0.95, 1.15)	1.00 (0.90, 1.11)
PhenoAgeAccel (SD = 7.11 years)			1.14 (1.04, 1.25)	1.08 (0.97, 1.19)
SA-Accel (SD = 10.37 years)			1.17 (1.08, 1.28)	1.14 (1.04, 1.24)
Sample B^a				
Aging constructs	No. of cancer survivors ^b	No. of controls ^b	OR (95% CI) per 1 SD increase in aging constructs	
			Model 1 ^c	Model 2 ^d
HannumAccel (SD = 5.20 years)	513	2,733	1.24 (1.10, 1.39)	1.22 (1.09, 1.37)
HorvathAccel (SD = 6.38 years)			1.14 (0.99, 1.30)	1.12 (0.98, 1.28)
LevineAccel (SD = 6.74 years)			1.15 (1.03, 1.28)	1.12 (1.00, 1.26)
GrimAgeAccel (SD = 4.65 years)			1.23 (1.10, 1.39)	1.21 (1.05, 1.41)
POA (SD = 0.09 years of physiological decline per one chronological year)			1.14 (0.99, 1.31)	1.11 (0.95, 1.29)

^aSample A includes participants who had measures of KDM-BA, PhenoAge, and SA. Sample B includes participants who data on ECs.

^bControls are participants without a history of cancer in 2016. Cancer survivors are participants with a history of cancer in 2016.

^cModel 1 was adjusted for chronological age.

^dModel 2 was adjusted for chronological age, sex, race/ethnicity, BMI, smoking status, comorbidity index, and CMV infection.